Chest
-
Multicenter Study
The use of cardiopulmonary bypass during resection of locally advanced thoracic malignancies: a 10-year two-center experience.
The use of cardiopulmonary bypass (CPB) for locally advanced thoracic malignancies is highly controversial. The purpose of this study was to document the techniques and results of CPB to facilitate the resection of complex thoracic malignancies and to identify common themes that provided for successful outcomes. This was a retrospective study that took place from January 1992 to September 2002. ⋯ The overall 1-year, 3-year, and 5-year survival rates were 57%, 36%, and 21%, respectively. The planned use of CPB to facilitate complete resection of thoracic malignancies should be considered only after careful patient selection. The availability of CPB also provides a safety net in the event of injury to vascular structures during tumor resection.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
To determine baseline characteristics predictive of response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. ⋯ Patients who benefit most when omalizumab is administered as add-on therapy are those receiving high doses of BDP, those with a history of frequent emergency asthma treatment, and those with poor lung function. Patients should be treated with omalizumab for a minimum duration of 12 weeks.